Core Viewpoint - The company expects a significant increase in net profit attributable to equity holders, projecting over RMB 240 million for the year ending December 31, 2025, which represents a year-on-year growth of approximately 139.4% compared to RMB 100.3 million for the year ending December 31, 2024 [1] - The group's revenue is anticipated to exceed RMB 1.05 billion, marking a year-on-year increase of about 34.6% from RMB 780 million for the year ending December 31, 2024 [1] Group Performance Drivers - Strong domestic sales growth of several flagship products, including the Qilin blood flow guiding device, neurovascular guidewires, UltraFree drug-eluting PTA balloon dilatation catheters, and Swan venous intraluminal radiofrequency closure catheters [1] - Successful market expansion in multiple regions leading to international sales growth of over 100% year-on-year [1] - Relatively stable gross margins combined with continuously improving operational efficiency [1]
归创通桥(02190)发盈喜，预期年度股东应占溢利净额将超过2.4亿元 同比增长约 139.4%